Drew McCormick joined JLL in 2019. Prior to joining JLL, Mr. McCormick was at Cain Brothers & Company in the Investment Banking division.
Mr. McCormick earned a B.B.A. and an M.P.A. in Accounting from The University of Texas McCombs School of Business
EVERSANA is a commercialization services provider that works with manufacturers, patients, payers and regulators to drive pharmaceutical products’ market access, affordability and adherence. Through the merger of seven highly regarded companies, JLL created a scaled, independent pharmaceutical services platform that services a wide range of biopharma customers (with an emphasis on niche pharmaceutical and generic manufacturers).
Outsourcing Trends: JLL expects the outsourced pharmaceutical commercialization industry to experience strong tailwinds due to growth in pharma R&D spend, an increase in expected new drug approvals, emergence of specialty pharmaceuticals, and increasing outsourced penetration. Commercialization services are still in the early stages of outsourcing and meaningfully lag drug development outsourcing.
Consolidation Opportunity: The pharma commercialization industry is highly fragmented today, and we believe that many opportunities exist to augment the company’s capability set and develop a comprehensive suite of outsourced commercialization services.
Leveraging Sector Expertise: Investing in EVERSANA provides an opportunity for JLL to build another successful company in the pharmaceutical services sector, expanding the firm’s strong track record in the industry (JLL has recently realized multiple investments in the outsourced pharmaceutical sector including Patheon, Bioclinica and PharmaNet).